GIANNECCHINI, SIMONE
 Distribuzione geografica
Continente #
NA - Nord America 3.263
EU - Europa 1.996
AS - Asia 521
AF - Africa 16
OC - Oceania 5
SA - Sud America 4
Totale 5.805
Nazione #
US - Stati Uniti d'America 3.239
IT - Italia 450
PL - Polonia 338
IE - Irlanda 330
SE - Svezia 225
UA - Ucraina 183
RU - Federazione Russa 180
HK - Hong Kong 160
JO - Giordania 125
CN - Cina 118
DE - Germania 105
FI - Finlandia 73
GB - Regno Unito 70
SG - Singapore 69
CA - Canada 24
TR - Turchia 15
SC - Seychelles 14
FR - Francia 12
BE - Belgio 8
CH - Svizzera 8
IN - India 8
VN - Vietnam 8
ES - Italia 7
JP - Giappone 6
AT - Austria 4
AU - Australia 3
BR - Brasile 3
IR - Iran 3
KR - Corea 3
KZ - Kazakistan 3
NL - Olanda 3
NZ - Nuova Zelanda 2
CL - Cile 1
EG - Egitto 1
MM - Myanmar 1
PK - Pakistan 1
SA - Arabia Saudita 1
ZA - Sudafrica 1
Totale 5.805
Città #
Fairfield 479
Warsaw 338
Dublin 330
Chandler 311
Jacksonville 247
Ashburn 232
Woodbridge 209
Seattle 184
Houston 179
Cambridge 170
Wilmington 153
Lawrence 128
Altamura 127
Florence 111
Princeton 100
Ann Arbor 91
Hong Kong 80
Medford 61
Beijing 58
Buffalo 49
Boston 44
Singapore 44
Boardman 43
San Diego 40
Milan 33
Moscow 30
Shanghai 23
Kent 19
Los Angeles 19
Norwalk 17
Toronto 14
Frankfurt Am Main 12
Hillsboro 12
West Jordan 12
London 11
Andover 9
Bern 8
Brussels 8
Dong Ket 8
Rome 8
Saint Petersburg 8
Auburn Hills 7
Falls Church 7
Izmir 7
Barcelona 6
New York 6
Chiswick 5
Lucca 5
Montottone 5
Verona 5
Chicago 4
Guangzhou 4
Kilburn 4
Menlo Park 4
Naples 4
Ottawa 4
San Giovanni Valdarno 4
Siena 4
Thiene 4
Vienna 4
Alvignano 3
Central 3
Cerro Maggiore 3
Piacenza 3
Redmond 3
Sesto Fiorentino 3
São Paulo 3
Trumbull 3
Almaty 2
Castelliri 2
Cattolica 2
Cheltenham 2
Coimbatore 2
Corzano 2
Groningen 2
Hakusan 2
Hounslow 2
Istanbul 2
Kiel 2
Lappeenranta 2
Laurel 2
Misano Adriatico 2
Montréal 2
Munich 2
Pisa 2
Pontassieve 2
Prato 2
Pune 2
Québec 2
Redwood City 2
San Piero A Sieve 2
Seoul 2
Shenzhen 2
Tiruchi 2
Washington 2
Wuhan 2
Wuxi 2
Astana 1
Auckland 1
Barrie 1
Totale 4.237
Nome #
Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy. 221
Investigation of in vitro replication features of wild ducks and turkey H7N3 influenza viruses: possibile role in interspecies transmission. 182
COVID-19 Salivary Signature: Diagnostic and Research Opportunities 110
Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab 103
Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein. 103
Comparison of in vitro replication features of H7N3 influenza viruses from wild ducks and turkeys: potential implications for interspecies transmission. 99
Packaging signals in the 5'-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules. 99
Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004-2017 98
Blood levels of TT virus following immune stimulation with influenza or hepatitis B vaccine. 97
Characterization of human H1N1 influenza virus variants selected In vitro with zanamivir in the presence of sialic acid-containing molecules 96
Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env 94
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies. 92
Utility of droplet digital PCR for the quantitative detection of polyomavirus JC in clinical samples 88
During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein. 87
Investigation on torquetenovirus (TTV) microRNA transcriptome in vivo 86
BK polyomavirus microRNA levels in exosomes are modulated by non-coding control region activity, and down-regulate viral replication when delivered to non-infected cells prior to infection. 86
Polyomavirus microRNAs circulating in biological fluids during viral persistence 86
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts. 85
Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy. 85
The JCPYV DNA load inversely correlates with the viral microrna expression in blood and cerebrospinal fluid of patients at risk of PML 83
A retro-inverso analogue of the antiviral octapeptide C8 inhibits feline immunodeficiency virus in serum. 82
Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. 81
Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates. 80
Feline immunodeficiency virus-infected cat sera associated with the development of broad neutralization resistance in vivo drive similar reversions in vitro. 80
Reassortment ability of the 2009 pandemic H1N1 influenza virus with circulating human and avian influenza viruses: Public health risk implications 78
The inhibition of a plant proteinase by lysine copolymers is modulated by the hydrophobicity of interposed amino acid side chains. 77
AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus. 77
Dissection of seroreactivity against the tryptophan-rich motif of feline immunodeficiency virus transmembrane glycoprotein. 77
Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy 76
Polyomavirus microRNA in saliva reveals persistent infectious status in the oral cavity 74
Development of antiviral fusion inhibitors: short modified peptides derived from the transmembrane glycoprotein of feline immunodeficiency virus 74
DDX3X helicase inhibitors as new strategy to fight West Nile Virus infection. 74
Oligonucleotides derived from the packaging signal at the 5’ end of the viral PB2 segment specifically inhibit influenza virus in vitro 73
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine. 72
The membrane-proximal tryptophan-rich region in the transmembrane glycoprotein ectodomain of feline immunodeficiency virus is important for cell entry. 70
Torquetenovirus (TTV) load is associated with mortality in Italian elderly subjects 70
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: homologous erythrocytes as a delivery system for preferential immunization with putative protective antigens. 68
Antiviral activity against SARS-CoV-2 of conformationally constrained helical peptides derived from angiotensin-converting enzyme-2. 67
Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats. 67
Feline immunodeficiency virus plasma load reduction by a retroinverso octapeptide reproducing the Trp-rich motif of the transmembrane glycoprotein 67
Multiple signatures of the JC polyomavirus in paired normal and altered colorectal mucosa indicate a link with human colorectal cancer, but not with cancer progression. 66
INCUBATION TIME FOR FELINE IMMUNODEFICIENCY VIRUS CULTURES. 65
Small RNAs targeting the 5' end of the viral polymerase gene segments specifically interfere with influenza type A virus replication 64
Molecular adaptation of an H7N3 wild duck influenza virus following experimental multiple passages in quail and turkey. 63
Torquetenovirus detection in exosomes enriched vesicles circulating in human plasma samples. 63
Detection of polyomavirus JC DNA and anti-JCV antibody in MS patients under natalizumab therapy. 62
Evolution of two amino acid positions governing broad neutralization resistence in a strain of feline immunodeficiency virus over 7 years of persistence in cats. 62
Pancreas rejection after pandemic influenzavirus A(H1N1)vaccination or infection: a report of two cases 59
Physicochemical characterization of a peptide deriving from the glycoprotein gp36 of the Feline Immunodeficiency Virus and its lipoylated analogue in micellar systems. 58
Increased pathogenicity and shedding in chickens of a wild bird origin LPAI virus of the H7N3 subtype following multiple in vivo passages in quail and turkey. 56
Are there lessons that can be learned from the FIV model ? 55
Moderate influenza vaccine effectiveness against A(H1N1)pdm09 virus, and low effectiveness against A(H3N2) subtype, 2018/19 season in Italy 55
Sudies on AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted. 53
Performance of at-home self-collected saliva and nasal-oropharyngeal swabs in the surveillance of COVID-19 53
Archetype JC polyomavirus DNA associated with extracellular vesicles circulates in human plasma samples. 52
Role of Env in the resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV, as determined using a chimeric virus 51
Effect of enzymatic deglycosylation on feline immunodeficiency virus sensitivity to antibody-mediated neutralization. 50
Changes in the SU can modulate the susceptibility of feline immunodeficiency virus to TM-derived entry inhibitors. 50
Reduced sensitivity to strain-specific neutralization of laboratory-adapted feline immunodeficiency virus after one passage in vivo: association with amino acid substitutions in V4 region of the surface glycoprotein. 49
I segnali di packaging alle estremità 5’ della regione codificante dei geni PA, PB1, E PB2 del virus dell’influenza come potenziali bersagli per lo sviluppo di antivirali. 46
Analisi dell’espressione di microRNA prodotti dal Polyomavirus JC. 45
In vitro selection of a human H1N1 influenza virus with zanamivir in presence of sialic acid-containing molecules changes its susceptibility to this inhibitor through substitutions in the neuraminidase and hemagglutinin. 44
Volatiles and Antifungal-Antibacterial-Antiviral Activity of South African Salvia spp. Essential Oils Cultivated in Uniform Conditions 44
Single-round virus replication assay for assisting the design of small molecules inhibiting HIV entry in host cells. 43
A unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses 43
Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizating antibodies. 43
Polyomavirus JC microRNAs expression after infection in vitro. 41
SARS-CoV-2: What Can Saliva Tell Us? 39
Selezione in vitro di varianti virali di virus dell’ influenza aviaria H7N3 dell’anatra in presenza di sialogangliosidi. 38
Antibodies generated in cats by a lipopeptide reproducing the MPER of the feline immunodeficiency virus TM enhance virus infectivity 38
Foamy virus derived vector as a tool to vaccinate against feline immunodeficiency virus. 37
Erratum: Pancreas rejection after pandemic influenzavirus A(H1N1) vaccination or infection: A report of two cases (Transplant International (2011) 24 (e28)) 37
Extracellular vesicles engagement during respiratory viruses infection 36
Screening of the essential oil effects on human H1N1 influenza virus infection: an in vitro study in MDCK cells 35
Detection of Polyomavirus microRNA-5p Expression in Saliva Short-Term after Kidney Transplantation 35
Detection of polyomavirus JC DNA and anti-JCV antibody in MS patients under natalizumab therapy. 34
Evidence of the mechanism by which polyomaviruses exploit the extracellular vesicle delivery system during infection 33
West Nile virus seroprevalence in the Italian Tuscany region from 2016 to 2019 32
Ricerca del Poliomavirus JC in pazienti con malattie reumatiche sottoposti ad un trattamento a lungo termine con infliximab. 31
null 30
Quantification of torque teno virus (TTV) DNA in saliva and plasma samples in patients at short time before and after kidney transplantation 29
Plasma Torquetenovirus (TTV) microRNAs and severity of COVID-19 29
Development of multiplex RT-PCR specific for the eight genomic segments of avian influenza A H7N3 viruses. 28
New influenza virus type A (H1N1), isolated in Florence. 28
A retroinverso peptide reproducing the Trp-rich motif of the FIV TM has favorable pharmacological traits and markedly reduces viral loads in a short-monotherapy experiment. 28
Development and in vitro characterization of short modified peptide inhibitors derived from TM gp of FIV for in vivo testing. 28
Antiviral activity of oligonucleotides targeting the SARS-CoV-2 genomic RNA stem-loop sequences within the 3’-end of the ORF1b. 28
Development of new antivirals against the influenza type A viruses based on small RNAs targeting the packaging signal of the polymarases gene coding region. 26
Torque teno virus microRNA detection in cerebrospinal fluids of patients with neurological pathologies 26
Polyomavirus JC detection in patients with rheumatic disease after a long-term treatment with infliximab. 25
Packaging signals in the 5' coding region of influenza virus PA, PB1, and PB2 genes as potential target to develop oligonucleotide based antiviral molecole. 25
MALDI-TOF mass spectrometry of saliva samples as a prognostic tool for COVID-19 23
Investigation of reassortment ability of pandemic H1N1 influenza virus with circulating human and avian influenza viruses. 22
SARS-CoV-2 inhibitory activity of a short peptide derived from internal fusion peptide of S2 subunit of spike glycoprotein 22
Preliminary evidence on the use of Polyomavirus JC microRNA as biomarker of viral reactivation 21
Studio in vitro della capacità di riassortimento del nuovo virus umano dell’influenza A di origine suina H1N1. 20
Identification of Novel Non-Nucleoside Inhibitors of Zika Virus NS5 Protein Targeting MTase Activity 18
Factors associated with death due to severe acute respiratory syndrome caused by influenza: Brazilian population study. 16
In vitro and ex vivo detection of human polyomavirus JC microRNA 16
Lack of direct association between oral mucosal lesions and SARS-CoV- 2 in a cohort of patients hospitalised with COVID-19 16
Totale 5.928
Categoria #
all - tutte 20.745
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.745


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020995 0 74 24 100 92 134 114 141 109 75 96 36
2020/2021829 61 47 55 126 38 110 34 82 59 101 55 61
2021/2022626 13 57 65 14 25 20 27 25 22 37 126 195
2022/20231.602 154 318 53 91 120 272 202 62 234 17 53 26
2023/2024583 26 87 116 38 39 34 31 110 14 41 32 15
2024/2025218 136 82 0 0 0 0 0 0 0 0 0 0
Totale 5.986